$CVRX

Binkowski Brent sold $3K of CVRX

Binkowski Brent (CHIEF OPERATING OFFICER) sold 1,309 shares of CVRx, Inc. (CVRX) at $2.55 on 2026-08-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Binkowski Brent
Published Aug 13, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CVRX
Neutral
medium confidence
Mentioned
$CVRX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CVRXNeutralLow
01

Why it matters

Insider selling can be interpreted as sentiment, but 10b5-1 plans are designed to reduce timing-based inference; the transaction size is small and lacks fundamental context.

02

Market read

A routine 10b5-1 insider sale was newly filed, offering limited incremental information for trading decisions.

03

What to watch

The filing does not state any new company-specific catalyst (earnings, guidance, trials, contracts), so traders should avoid over-weighting it versus fundamentals.

Relevance 2/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-08-13)

Background

The article is an SEC Form 4 insider transaction disclosure for CVRx, Inc.

Company-level read

Ticker impact

$CVRXNeutralMedium confidence
Context

CVRx disclosed an insider open-market sale by its COO: 1,309 shares sold at $2.5502 on 2026-08-12 under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

Form 4 shows a pre-arranged 10b5-1 sale with modest dollar value ($3,338.21) and no accompanying operational or financial guidance change.

Market effects

No clear sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • CVRx, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Binkowski Brent

    Chief Operating Officer who sold shares in an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CVRXMedAI 8/10

CVRx (CVRX) Q2 2026 Earnings Call Transcript

CVRx (CVRX) reported Q2 2026 revenue of $15.7 million, up 16%, driven by U.S. heart failure sales. U.S. revenue rose 21% to $14.8 million; Europe revenue fell 31% to $0.9 million. Gross margin was 87%. Full-year 2026 revenue guidance was lowered to $58 million to $60 million. Management cited reimbursement headwinds, sales productivity strain, and a DOJ civil investigative demand.

$CVRXMed

CVRx, Inc. (CVRX): Results of Operations and Financial Condition

CVRx, Inc. (CVRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CVRx Reports Second Quarter 2026 Financial and Operating Results MINNEAPOLIS, August 6, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromod